Local antihistamines

Trigg, C.J.; Davies, Robert J.

doi:10.1111/j.1365-2222.1996.tb00495.x

Cited by 9 publications

(2 citation statements)

References 27 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, despite their potent anti-inflammatory properties, the use of this class of drugs may be limited because of concerns over unwanted side-effects [17]. In contrast, H 1 -antihistamines are commonly used as the firstline treatment for AR [17][18][19]. There is much evidence that certain H 1 -antihistamines may possess anti-inflammatory activities in addition to blocking the action of histamine at the receptors, thus conferring a therapeutic advantage in the treatment and management of allergic diseases [20,21].…”

Section: Introductionmentioning

confidence: 99%

Suppressive activity of fexofenadine hydrochloride on metalloproteinase production from nasal fibroblasts in vitro

Asano¹,

Kanai

Suzaki

2004

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Suppressive activity of fexofenadine hydrochloride on metalloproteinase production from nasal fibroblasts in vitro

Asano¹,

Kanai

Suzaki

2004

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…At the cellular level, histamine causes smooth muscle contraction, increased vascular permeability and mucus secretion and parasympathetic nerve stimulation [2,3]. It may also act on inflammatory cells and lead to release of mediators, such as leukotrienes and cytokines, and increased expression of MHC class II antigens (HLA-DR) and ICAM-1 on epithelial cells [4,5].…”

Section: Introductionmentioning

confidence: 99%

Effect of antihistamines on epithelial cells

Devalia

Davies

1999

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

Antihistamines have mostly been used in the management of allergic rhinitis, primarily for their symptomatic relief. Recent studies, however, have suggested that the non-sedating second-generation antihistamines also possess anti-inflammatory activity, and consequently may be useful in the management of inflammation in allergic airways disease. Several in vivo studies have demonstrated that antihistamines decrease inflammatory cell infiltration in allergic disease, mediator release from mast/basophil cells, and the expression of adhesion molecules on epithelial cells. Similarly, in vitro studies have demonstrated that antihistamines decrease the migration and activation of eosinophils and the release of pro-inflammatory mediators from mast/basophil cells, induced by immunological and non-immunological stimuli. More recent evidence suggests that the antihistamines may modulate airway inflammation by influencing the activity of airway epithelial cells, which due to their spatial arrangement and predominance in the airways, are thought to play a pivotal role in the aetiology of airway disease. We and others have demonstrated that antihistamines attenuate allergen- or chemical-induced expression and/or release of mediators which influence the activity of inflammatory cells, such as eosinophils, mast cells, basophils and lymphocytes, known to be involved in the pathogenesis of allergic airway diseases. Collectively, these studies suggest that second-generation H1-histamine receptor antagonists may have potential use either as safe anti-inflammatory alternatives to corticosteroids, or as rescue medication in combination with corticosteroids, for the management of severe airway disease.

show abstract